Neogenomics Inc. (NASDAQ:NEO) shares, rose in value, with the stock price up by 2.09% to the previous day’s close as strong demand from buyers drove the stock to $14.14.
Actively observing the price movement in the last trading, the stock closed the session at $13.85. Referring to stock’s 52-week performance, its high was $21.22, and the low was $11.03. On the whole, NEO has fluctuated by -6.97% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 654.56M, with a low estimate of 148.1M and a high estimate of 152M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 149.89M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NEO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of NEO currently trading nearly -1.70% and -5.96% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 46.24, while the 7-day volatility ratio is showing 4.45% which for the 30-day chart, stands at 4.11%. Furthermore, Neogenomics Inc. (NEO)’s beta value is 1.12, and its average true range (ATR) is 0.60.
A comparison of Neogenomics Inc. (NEO) with its peers suggests the former has fared considerably weaker in the market. NEO showed an intraday change of 2.09% in last session, and over the past year, it shrunk by -1.81%%.
Data on historical trading for Neogenomics Inc. (NASDAQ:NEO) indicates that the trading volumes over the past 3 months, they’ve averaged 900.46K. According to company’s latest data on outstanding shares, there are 127.37 million shares outstanding.
Nearly 1.16% of Neogenomics Inc.’s shares belong to company insiders and institutional investors own 99.16% of the company’s shares. The stock has fallen by -12.61% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NEO stock heading into the next quarter.
